In all cases these patients had a sarcoma subtype or connective tissue tumor with no other standard option (AF, angiosarcoma, chordoma...), and were treated with imatinib, sorafenib, or mTOR inhibitors. The gene discussed is MTOR; the disease is angiosarcoma.